Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Pharmaceutical Manufacturing and Sales	1.60T	1.46T	1.41T	1.32T	1.18T
Pharmaceutical Manufacturing and Sales Growth	9.79%	3.45%	7.06%	11.17%	9.68%
Service Provision	40.46B	38.40B	23.65B	9.84B	7.80B
Service Provision Growth	5.38%	62.37%	140.29%	26.22%	26.90%
Other	3.03B	7.19B	8.26B	5.23B	1.47B
Other Growth	-57.92%	-12.94%	57.92%	257.10%	-4.88%
Consolidation	-73.37B	-81.00B	-66.10B	-51.58B	-40.58B
Total	1.57T	1.42T	1.38T	1.28T	1.15T
Total Growth	10.42%	3.44%	7.44%	11.03%	9.24%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Export	275.83B	252.56B	212.15B	184.96B	117.89B
Export Growth	9.21%	19.05%	14.70%	56.89%	26.87%
South Korea	1.37T	1.25T	1.23T	1.15T	1.08T
South Korea Growth	9.38%	1.78%	7.20%	6.61%	8.15%
Consolidation	-73.37B	-81.00B	-66.10B	-51.58B	-40.58B
Total	1.57T	1.42T	1.38T	1.28T	1.15T
Total Growth	10.42%	3.44%	7.44%	11.03%	9.24%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 17, 2026

Data Sources Report a data error